

**7. BIBLIOGRAFÍA**

- 
1. Harris EN, Gharavi AE, Hughes GRV. Anti-phospholipid antibodies. *Clin Rheum Dis* 1985; 11: 591-609.
  2. Cervera R, Piette JC, Font J, Khamashta MA, Shoenfeld Y, Camps MT et al. Antiphospholipid syndrome. Clinical and immunologic manifestations and patterns of disease expression in a cohort of 1,000 patients. *Arthritis Rheum* 2002; 46: 1019-1027.
  3. Cervera R, Khamashta MA, Font J, Sebastiani GD, Gil A, Lavilla P et al. Systemic lupus erythematosus: clinical and immunologic patterns of disease expression in a cohort of 1000 patients. *Medicine (Baltimore)* 1993; 72:113-124.
  4. Vianna JL, Khamashta MA, Ordi-Ros J, Font J, Cervera R, Lopez-Soto A et al. Comparison of the primary and secondary antiphospholipid syndrome: a european multicenter study of 114 patients. *Am J Med* 1994; 96: 3-9.
  5. Harris EN. Antiphospholipid antibodies. *Br J Haematol* 1990; 74: 1-9.
  6. Alarcón-Segovia D, Pérez-Vázquez ME, Villa AR, Drenkard C, Cabiedes J. Preliminary classification criteria for the antiphospholipid syndrome within systemic lupus erythematosus. *Semin Arthritis Rheum* 1992; 21: 275-286.
  7. Wilson WA, Gharavi AE, Koike T, Lockshin MD, Branch DW, Piette J et al. International consensus statement on preliminary classification criteria for definite antiphospholipid syndrome. *Arthritis Rheum* 1999; 42:1309-1311.

- 
8. Piette JC, Wechsler B, Francès C, Papo T, Godeau P. Exclusion criteria for primary antiphospholipid syndrome. *J Rheumatol* 1993; 20: 1802-1804.
  9. Seisdedos L, Muñoz-Rodríguez FJ, Cervera R, Font J, Ingelmo M. Primary antiphospholipid syndrome evolving into systemic lupus erythematosus. *Lupus* 1997; 6: 285-286.
  10. Goel N, Ortel TL, Bali D, Anderson JP, Gourley IS, Smith H et al. Familial antiphospholipid syndrome. Criteria for disease and evidence for autosomal dominant inheritance. *Arthritis Rheum* 1999; 42: 318-327.
  11. Asherson RA, Khamashta MA, Ordi-Ros J, Derksen RHW, Machin SJ, Path FRC et al. The primary antiphospholipid syndrome: major clinical and serological features. *Medicine* 1989; 68: 366-374.
  12. Asherson RA, Baguley E, Pal C, Hughes GRV. Antiphospholipid syndrome: five years follow up. *Ann Rheum Dis* 1991; 50: 805-810.
  13. Khamashta MA, Hughes GRV. Antiphospholipid antibodies and antiphospholipid syndrome. *Curr Opin Rheumatol* 1995; 7: 389-394.
  14. Levine JS, Branch DW, Rauch J. The antiphospholipid syndrome. *N Engl J Med* 2002; 346: 752-763.
  15. Cervera R, Asherson RA, Lie JT. Clinicopathologic correlations of the antiphospholipid syndrome. *Semin Arthritis Rheum* 1995; 24: 262-272.

16. Hughson MD, McCarty GA, Brumback RA. Spectrum of vascular pathology affecting patients with the antiphospholipid syndrome. *Hum Pathol* 1995; 26: 716-724.
17. Rosove MH, Brewer PMC. Antiphospholipid thrombosis: clinical course after the first thrombotic event in 70 patients. *Ann Intern Med* 1992; 117:303-308.
18. Krnic-Barrie S, O'Connor CR, Looney SW, Pierangeli SS, Harris EN. A retrospective review of 61 patients with antiphospholipid syndrome. Analysis of factors influencing recurrent thrombosis. *Arch Intern Med* 1997; 157:2101-2108.
19. Khamashta MA, Cuadrado MJ, Mujic F, Taub NA, Hunt BJ, Hughes GRV. The management of thrombosis in the antiphospholipid-antibody syndrome. *N Engl J Med* 1995; 332: 993-997.
20. Insko EK, Haskal ZJ. Antiphospholipid syndrome: patterns of life-threatening and severe recurrent vascular complications. *Radiology* 1997; 202:319-326.
21. Asherson RA, Cervera R. Antiphospholipid antibodies and the lung. *J Rheumatol* 1995; 22: 62-66.
22. Sandoval J, Amigo MC, Barragan R, Izaguirre R, Reyes PA, Martinez-Guerra ML et al. Primary antiphospholipid syndrome presenting as chronic thromboembolic pulmonary hypertension. Treatment with thromboendarterectomy. *J Rheumatol* 1996; 23: 772-775.

- 
23. Montalbán J, Ordi J, Barquinero J, Vilardell M. Sneddon's syndrome and anticardiolipin antibodies. *Stroke* 1988; 19: 785-786.
24. Francès C, Papo T, Wechsler B, Laporte JL, Biousse V, Piette JC. Sneddon syndrome with or without antiphospholipid antibodies. A comparative study in 46 patients. *Medicine* 1999; 78: 209-219.
25. Levine SR, Deegan MJ, Futrell N, Welch KMA. Cerebrovascular and neurologic disease associated with antiphospholipid antibodies: 48 cases. *Neurology* 1990; 40: 1190-1196.
26. Brey RL, Gharavi AE, Lockshin MD. Neurologic complications of antiphospholipid antibodies. *Rheum Dis Clin North Am* 1993; 19: 833-850.
27. Levine SR, Brey RL. Neurological aspects of antiphospholipid antibody syndrome. *Lupus* 1996; 5: 347-353.
28. Cuadrado MJ, Khamashta MA, Ballesteros A, Godfrey T, Simon MJ, Hughes GRV. Can neurologic manifestations of Hughes (antiphospholipid) syndrome be distinguished from multiple sclerosis? Analysis of 27 patients and review of the literature. *Medicine* 2000; 79: 57-68.
29. Ford SE, Ford PM. The cardiovascular pathology of antiphospholipid antibodies: an illustrative case and review of the literature. *Cardiovasc Pathol* 1995; 4: 111-122.

- 
30. Cervera R, Khamashta MA, Font J, Reyes PA, Vianna JL, Lopez-Soto A et al. High prevalence of significant heart valve lesions in patients with the primary antiphospholipid syndrome. *Lupus* 1991; 1: 43-47.
31. Barbut D, Borer JS, Gharavi A, Wallerson D, Devereux RB, Supino P et al. Prevalence of anticardiolipin antibody in isolated mitral or aortic regurgitation, or both, and possible relation to cerebral ischemic events. *Am J Cardiol* 1992; 70: 901-905.
32. Barbut D, Borer JS, Wallerson D, Ameisen O, Lockshin M. Anticardiolipin antibody and stroke: possible relation of valvular heart disease and embolic events. *Cardiology* 1991; 79: 99-109.
33. Verro P, Levine SR, Tietjen GE. Cerebrovascular ischemic events with high positive anticardiolipin antibodies. *Stroke* 1998; 29: 2245-2253.
34. Amigo MC, Garcia-Torres R, Robles M, Bochicchio T, Reyes PA. Renal involvement in primary antiphospholipid syndrome. *J Rheumatol* 1992; 19: 1181-1185.
35. Asherson RA, Kant KS. Antiphospholipid antibodies and the kidney. *J Rheumatol* 1993; 20: 1268-1272.
36. Brady L, Magilavy D, Black DD. Portal vein thrombosis associated with antiphospholipid antibodies in a child. *J Pediatr Gastroenterol Nutr* 1996; 23: 470-473.
37. Espinosa G, Font J, Garcia-Pagan JC, Tàssies D, Reverter JC, Gaig C et al. Budd-Chiari syndrome secondary to antiphospholipid syndrome.

- 
- Clinical and immunologic characteristics of 43 patients. *Medicine* 2001; 80: 345-354.
38. Castañón C, Amigo MC, Bañales JL, Nava A, Reyes PA. Ocular vaso-occlusive disease in primary antiphospholipid syndrome. *Ophthalmology* 1995; 102: 256-262.
39. Reino S, Muñoz-Rodríguez FJ, Cervera R, Espinosa G, Font J, Ingelmo M. Optic neuropathy in the primary antiphospholipid syndrome: report of a case and review of the literature. *Clin Rheumatol* 1997; 16: 629-631.
40. Gibson GE, Su WPD, Pittelkow MR. Antiphospholipid syndrome and the skin. *J Am Acad Dermatol* 1997; 36: 970-982.
41. Asherson RA, Cervera R, Piette JC, Shoenfeld Y, Espinosa G, Petri MA et al. Catastrophic antiphospholipid syndrome. Clues to the pathogenesis from a series of 80 patients. *Medicine (Baltimore)* 2001; 80: 355-377.
42. Cuadrado MJ, Mujic F, Muñoz E, Khamashta MA, Hughes GRV. Thrombocytopenia in the antiphospholipid syndrome. *Ann Rheum Dis* 1997; 56:194-196.
43. Diz-Küçükaya R, Hacıhanefioğlu A, Yenerel M, Turgut M, Keskin H, Nalçacı M et al. Antiphospholipid antibodies and antiphospholipid syndrome in patients presenting with immune thrombocytopenic purpura: a prospective cohort study. *Blood* 2001; 98: 1760-1764.
44. Balasch J, Font J, López-Soto A, Cervera R, Jové I, Casals FJ et al. Antiphospholipid antibodies in unselected patients with repeated abortion. *Hum Reprod* 1990; 5: 43-46.

45. Rai RS, Clifford K, Cohen H, Regan L. High prospective fetal loss rate in untreated pregnancies of women with recurrent miscarriage and antiphospholipid antibodies. *Hum Reprod* 1995; 10:3301-3304.
46. Lynch A, Marlar R, Murphy J, Davila G, Santos M, Rutledge J et al. Antiphospholipid antibodies in predicting adverse pregnancy outcome. *Ann Intern Med* 1994; 120: 470-475.
47. Lima F, Khamashta MA, Buchanan NMM, Kerslake S, Hunt BJ, Hughes GRV. A study of sixty pregnancies in patients with the antiphospholipid syndrome. *Clin Exp Rheumatol* 1996; 14:131-136.
48. Balasch J, Carmona F, López-Soto A, Font J, Creus M, Fábregues F et al. Low-dose aspirin for prevention of pregnancy losses in women with primary antiphospholipid syndrome. *Hum Reprod* 1993; 8: 2234-2239.
49. Oshiro BT, Silver RM, Scott JR, Yu H, Branch DW. Antiphospholipid antibodies and fetal death. *Obstet Gynecol* 1996; 87: 489-493.
50. Triplett DA, Harris EN. Antiphospholipid antibodies and reproduction. *Am J Reprod Immunol* 1989; 21: 123-131.
51. Levine M, Gent M, Hirsh J, Leclerc J, Anderson D, Weitz J et al. A comparison of low-molecular-weight heparin administered primarily at home with unfractionated heparin administered in the hospital for proximal deep-vein thrombosis. *N Engl J Med* 1996; 334: 677-681.
52. The Columbus Investigators. Low-molecular-weight heparin in the treatment of patients with venous thromboembolism. *N Engl J Med* 1997; 337: 657-662.



53. Simonneau G, Sors H, Charbonnier B, Page Y, Laaban JP et al. A comparison of low-molecular-weight heparin with unfractionated heparin for acute pulmonary embolism. *N Engl J Med* 1997; 337: 663-669.
54. Khamashta MA. Management of thrombosis in the antiphospholipid syndrome. *Lupus* 1996; 5: 463-466.
55. Palareti G, Leali N, Coccheri S, Poggi M, Manotti C, D'Angelo A et al. Bleeding complications of oral anticoagulant treatment: an inception-cohort, prospective collaborative study (ISCOAT). *Lancet* 1996; 348: 423-428.
56. Greaves M, Cohen H, Machin SJ, Mackie I. Guidelines on the investigation and management of the antiphospholipid syndrome. *Br J Haematol* 2000; 109: 704-715.
57. Della Valle P, Crippa L, Safa O, Tomassini L, Pattarini E, Viganò-D'Angelo S et al. Potential failure of the international normalized ratio (INR) system in the monitoring of oral anticoagulation in patients with lupus anticoagulants. *Ann Med Interne (Paris)* 1996; 147:10-14.
58. Moll S, Ortel TL. Monitoring warfarin therapy in patients with lupus anticoagulants. *Ann Intern Med* 1997; 127:177-185.
59. Fiore LD, Ezekowitz MD, Brophy MT, Lu D, Sacco J, Peduzzi P. Department of Veterans Affairs Cooperative Studies Program Clinical Trial comparing combined warfarin and aspirin with aspirin alone in survivors of acute myocardial infarction: primary results of the CHAMP study. *Circulation* 2002; 105: 557-563.

60. Roubey RA. Treatment of the antiphospholipid syndrome. *Curr Opin Rheumatol* 2002; 14: 238-242.
61. Levy RA, Avvad E, Oliveira J, Porto LC. Placental pathology in antiphospholipid syndrome. *Lupus* 1998; 7: S81-S85.
62. Granger KA, Farquharson RG. Obstetric outcome in antiphospholipid syndrome. *Lupus* 1997; 6: 509-513.
63. Kutteh WH. Antiphospholipid antibody-associated recurrent pregnancy loss: treatment with heparin and low-dose aspirin is superior to low-dose aspirin alone. *Am J Obstet Gynecol* 1996; 174:1584-1589.
64. Rai R, Cohen H, Dave M, Regan L. Randomised controlled trial of aspirin and aspirin plus heparin in pregnant women with recurrent miscarriage associated with phospholipid antibodies (or antiphospholipid antibodies). *BMJ* 1997; 314:253-257.
65. Pattison NS, Chamley LW, Birdsall M, Zanderigo AM, Liddell HS, McDougall J. Does aspirin have a role in improving pregnancy outcome for women with the antiphospholipid syndrome? A randomized controlled trial. *Am J Obstet Gynecol* 2000; 183: 1008-1012.
66. Cowchock FS, Reece EA, Balaban D, Branch DW, Plouffe L. Repeated fetal losses associated with antiphospholipid antibodies: a collaborative randomized trial comparing prednisone with low-dose heparin treatment. *Am J Obstet Gynecol* 1992; 155: 1318-1323.

67. Lockshin MD, Druzin ML, Qamar T. Prednisone does not prevent recurrent fetal death in women with antiphospholipid antibody. *Am J Obstet Gynecol* 1989; 160: 439-443.
68. Conley CL, Hartman RC. Hemorrhagic disorder caused by circulating anticoagulants in patients with disseminated lupus erythematosus. *J Clin Invest* 1952; 150:621-622.
69. Bowie EJW, Thompson JH, Pescuzzi CA, Owen CA. Thrombosis in systemic lupus erythematosus despite circulating anticoagulants. *J Lab Clin Med* 1963; 62: 416-430.
70. Feinstein DI, Rapaport SI. Acquired inhibitors of blood coagulation. *Haemostas Thromb* 1972; 1:75-95.
71. Pierangeli SS, Goldsmith GH, Branch DW, Harris EN. Antiphospholipid antibody: functional specificity for inhibition of prothrombin activation by the prothrombinase complex. *Br J Haematol* 1997; 97:768-774.
72. Court EL. Lupus anticoagulants: pathogenesis and laboratory diagnosis. *Br J Biomed Sci* 1997; 54:287-298.
73. Brandt JT, Barna LK, Triplett DA. Laboratory identification of lupus anticoagulants: results of The Second International Workshop for identification of lupus anticoagulants. *Thromb Haemost* 1995; 74:1597-1603.

74. Gharavi AE, Harris EN, Asherson RA, Hughes GRV. Anticardiolipin antibodies: isotype distribution and phospholipid specificity. *Ann Rheum Dis* 1987; 46:1-6.
75. McNeil HP, Simpson RJ, Chesterman CN, Krilis SA. Antiphospholipid antibodies are directed against a complex antigen that includes a lipid-binding inhibitor of coagulation:  $\beta$ 2-glycoprotein I (apolipoprotein H). *Proc Natl Acad Sc USA* 1990; 87:4120-4124.
76. Galli M, Comfurius P, Maassen C, Hemker HC, De Baets MH, Van Breda-Vriesman PJC et al. Anticardiolipin antibodies (ACA) directed not to cardiolipin but to a plasma protein cofactor. *Lancet* 1990; 335:1544-1547.
77. Matsuura E, Igarashi Y, Fujimoto M, Ichikawa K, Koike T. Anticardiolipin cofactor(s) and differential diagnosis of autoimmune disease. *Lancet* 1990; 336:177-178.
78. Matsuura E, Igarashi Y, Yasuda T, Triplett DA, Koike T. Anticardiolipin antibodies recognize  $\beta$ 2-glycoprotein I structure altered by interacting with an oxygen-modified solid phase surface. *J Exp Med* 1994; 179:457-462.
79. Foratiero RR, Martinuzzo ME, Kordich LC, Carreras LO. Reactivity to  $\beta$ 2-glycoprotein I clearly differentiates anticardiolipin antibodies from antiphospholipid syndrome and syphilis. *Thromb Haemost* 1996; 75:717-720.

80. Abuaf N, Laperche S, Rajoely B, Carsique R, Deschamps A, Rouquette AM et al. Autoantibodies to phospholipids and to the coagulation proteins in AIDS. *Thromb Haemost* 1997; 77: 856-861.
81. Oosting JD, Derksen RHWM, Entjes HTI, Bouma BN, De Groot PG. Lupus anticoagulant activity is frequently dependent on the presence of  $\beta$ 2-glycoprotein I. *Thromb Haemost* 1992; 67:499-502.
82. Bevers EM, Galli M, Barbui T, Comfurius P, Zwaal RFA. Lupus anticoagulant IgG's (LA) are not directed to phospholipids only, but to a complex of lipid-bound human prothrombin. *Thromb Haemost* 1991; 66:629-632.
83. Horbach DA, V. Oort E, Donders RCJM, Derksen RHWM, de Groot PG. Lupus anticoagulant is the strongest risk factor for both venous and arterial thrombosis in patients with systemic lupus erythematosus. *Thromb Haemost* 1996; 76:916-924.
84. Wahl DG, Guillemin F, De Maistre E, Perret-Guillaume C, Lecompte T, Thibaut G. Meta-analysis of the risk of venous thrombosis in individuals with antiphospholipid antibodies without underlying autoimmune disease or previous thrombosis. *Lupus* 1998; 7:15-22.
85. Galli M, Finazzi G, Norbis F, Marziali S, Marchioli R, Barbui T. The risk of thrombosis in patients with lupus anticoagulants is predicted by their specific coagulation profile. *Thromb Haemost* 1999; 81: 695-700.

86. Galli M, Finazzi G, Bevers EM, Barbui T. Kaolin clotting time and dilute Russell's viper venom time distinguish between prothrombin- and  $\beta$ 2-glycoprotein I-dependent antiphospholipid antibodies. *Blood* 1995; 86: 617-623.
87. Tsutsumi A, Matsuura E, Ichikawa K, Fujisaku A, Mukai M, Kobayashi S et al. Antibodies to  $\beta$ 2-glycoprotein I and clinical manifestations in patients with systemic lupus erythematosus. *Arthritis Rheum* 1996; 39:1466-1474.
88. Amengual O, Atsumi T, Khamashta MA, Koike T, Hughes GRV. Specificity of ELISA for antibody to  $\beta$ 2-glycoprotein I in patients with antiphospholipid syndrome. *Br J Rheumatol* 1996; 35:1239-1243.
89. Teixidó M, Font J, Reverter JC, Cervera R, Tàssies D, Ingelmo M et al. Anti- $\beta$ 2-glycoprotein I antibodies: a useful marker for the antiphospholipid syndrome. *Br J Rheumatol* 1997; 36:113-116.
90. Arvieux J, Darnige L, Caron C, Reber G, Bensa JC, Colomb MG. Development of an ELISA for autoantibodies to prothrombin showing their prevalence in patients with lupus anticoagulants. *Thromb Haemost* 1995; 74:1120-1125.
91. Corrigan JJ, Patterson JH, May NE. Incoagulability of the blood in systemic lupus erythematosus. A case due to hypoprothrombinemia and a circulating anticoagulant. *Am J Dis Child* 1970; 119: 365-369.

92. Bajaj SP, Rapaport SI, Fierer DS, Herbst KD, Schwartz DB. A mechanism for the hypoprothrombinemia of the acquired hypoprothrombinemia-lupus anticoagulant syndrome. *Blood* 1983; 61: 684-692.
93. Edson JR, Vogt JM, Hasegawa DK. Abnormal prothrombin crossed-immunoelectrophoresis in patients with lupus inhibitors. *Blood* 1984; 64: 807-816.
94. Fleck RA, Rapaport SI, Rao LVM. Anti-prothrombin antibodies and the lupus anticoagulant. *Blood* 1988; 72: 512-519.
95. Galli M, Beretta G, Daldossi M, Bevers EM, Barbui T. Different anticoagulant and immunological properties of anti-prothrombin antibodies in patients with antiphospholipid antibodies. *Thromb Haemost* 1997; 77: 486-491.
96. Galli M, Barbui T. Antiprothrombin antibodies: detection and clinical significance in the antiphospholipid syndrome. *Blood* 1999; 93: 2149-2157.
97. Horbach DA, van Oort E, Derksen RHWM, de Groot PG. The contribution of anti-prothrombin-antibodies to lupus anticoagulant activity. *Thromb Haemost* 1998; 79: 790-795.
98. Vaarala O, Puurunen M, Manttari M, Manninen V, Aho K, Palosuo T. Antibodies to prothrombin imply a risk of myocardial infarction in middle-aged men. *Thromb Haemost* 1996; 75:456-459.

- 
99. Palosuo T, Virtamo J, Haukka J, Taylor PR, Aho K, Puurunen M et al. High antibody levels to prothrombin imply a risk of deep venous thrombosis and pulmonary embolism in middle-aged men. *Thromb Haemost* 1997; 78:1178-1182.
100. Pengo V, Biasiolo A, Brocco T, Tonetto S, Ruffatti A. Autoantibodies to phospholipid-binding plasma proteins in patients with thrombosis and phospholipid-reactive antibodies. *Thromb Haemost* 1996; 75:721-724.
101. Swadzba J, De Clerck L, Stevens WJ, Bridts CH, Van Cotthem KA, Musial J et al. Anticardiolipin, anti- $\beta$ 2-glycoprotein I, antiprothrombin antibodies, and lupus anticoagulant in patients with systemic lupus erythematosus with a history of thrombosis. *J Rheumatol* 1997; 24:1710-1715.
102. Forastiero RR, Martinuzzo ME, Cerrato GS, Kordich LC, Carreras LO. Relationship of anti- $\beta$ 2-glycoprotein I and anti-prothrombin antibodies to thrombosis and pregnancy loss in patients with antiphospholipid antibodies. *Thromb Haemost* 1997; 78:1008-1014.
103. Bertolaccini ML, Atsumi T, Khamashta MA, Amengual O, Hughes GRV. Autoantibodies to human prothrombin and clinical manifestations in 207 patients with systemic lupus erythematosus. *J Rheumatol* 1998; 25:1104-1108.
104. Atsumi T, Ieko M, Bertolaccini ML, Ichikawa K, Tsutsumi A, Matsuura E et al. Association of autoantibodies against the phosphatidylserine-



- 
- prothrombin complex with manifestations of the antiphospholipid syndrome and with the presence of lupus anticoagulant. *Arthritis Rheum* 2000; 43: 1982-1993.
105. Permpikul P, Rao LVM, Rapaport SI. Functional and binding studies of the roles of prothrombin and  $\beta$ 2-glycoprotein I in the expression of lupus anticoagulant activity. *Blood* 1994; 83: 2878-2892.
106. Rao LVM, Hoang AD, Rapaport SI. Mechanism and effects of the binding of lupus anticoagulant IgG and prothrombin to surface phospholipid. *Blood* 1996; 88: 4173-4182.
107. Rand JH, Wu XX, Andree HAM, Lockwood CJ, Guller S, Scher J et al. Pregnancy loss in the antiphospholipid-antibody syndrome - a possible thrombogenic mechanism. *N Engl J Med* 1997; 337: 154-160.
108. Zhao Y, Rumold R, Zhu M, Zhou D, Ahmed AE, Le DT et al. An IgG antiprothrombin antibody enhances prothrombin binding to damaged endothelial cells and shortens plasma coagulation times. *Arthritis Rheum* 1999; 42: 2132-2138.
109. Haj-Yahja S, Sherer Y, Blank M, Kaetsu H, Smolinsky A, Shoenfeld Y. Anti-prothrombin antibodies cause thrombosis in a novel qualitative *ex-vivo* animal model. *Lupus* 2003; 12: 364-369.
110. Nojima J, Kuratsune H, Suehisa E, Kawasaki T, Machii T, Kitani T et al. Acquired activated protein C resistance is associated with the co-existence of anti-prothrombin antibodies and lupus anticoagulant activity

- 
- in patients with systemic lupus erythematosus. *Br J Haematol* 2002; 118: 577-583.
111. Simmelink MJA, Fernández JA, Derksen RHW, Griffin JH, de Groot PG. Low levels of activated protein C in patients with systemic lupus erythematosus do not relate to lupus anticoagulants but to low levels of factor II. *Br J Haematol* 2002; 117: 676-684.
112. Puurunen M, Mänttari M, Manninen V, Palosuo T, Vaarala O. Antibodies to prothrombin crossreact with plasminogen in patients developing myocardial infarction. *Br J Haematol* 1998; 100: 374-379.
113. Blank M, Cohen J, Toder V, Shoenfeld Y. Induction of antiphospholipid syndrome in naive mice with mouse lupus monoclonal and human polyclonal anti-cardiolipin antibodies. *Proc Natl Acad Sci U.S.A.* 1991; 88: 3069-3073.
114. Bakimer R, Fishman P, Blank M, Sredni B, Djaldetti M, Shoenfeld Y. Induction of primary anti-phospholipid syndrome in mice by immunization with a human monoclonal anti-cardiolipin antibody (H-3). *J Clin Invest* 1992; 89: 1558-1563.
115. Roubey RAS. Immunology of the antiphospholipid antibody syndrome. *Arthritis Rheum* 1996; 39:1444-1454.
116. Clouse LH, Comp PC. The regulation of hemostasis: the protein C system. *N Engl J Med* 1986; 314: 1298-1304.

117. Tsakiris DA, Settas L, Makris PE, Marbet GA. Lupus anticoagulant – antiphospholipid antibodies and thrombophilia. Relation to protein C – protein S – Thrombomodulin. *J Rheumatol* 1990; 17: 785-789.
118. Parke AL, Weinstein RE, Bona RD, Maier DB, Walker FJ. The thrombotic diathesis associated with the presence of phospholipid antibodies may be due to low levels of free protein S. *Am J Med* 1992; 93: 49-56.
119. Tomas JF, Alberca I, Taberner MD, Cordero M, Del Pino-Montes J, Vicente V. Natural anticoagulant proteins and antiphospholipid antibodies in systemic lupus erythematosus. *J Rheumatol* 1998; 25: 57-62.
120. Reverter JC, Tassies D, Font J, Monteagudo J, Escolar G, Ingelmo M et al. Hypercoagulable state in patients with antiphospholipid syndrome is related to high induced tissue factor expression on monocytes and to low free protein S. *Arterioscler Thromb Vasc Biol* 1996; 16: 1319-1326.
121. Atsumi T, Khamashta MA, Ames PRJ, Ichikawa K, Koike T, GRV Hughes. Effect of  $\beta$ 2glycoprotein I and human monoclonal anticardiolipin antibody on the protein S/C4b-binding protein system. *Lupus* 1996; 6: 358-364.
122. Keeling DM, Campbell SJ, Mackie IJ, Machin SJ, Isenberg DA. Total and free protein S in systemic lupus erythematosus. *Thromb Res* 1990; 60: 237-240.

- 
123. Malia RG, Kitchen S, Greaves M, Preston FE. Inhibition of activated protein C and its cofactor protein S by antiphospholipid antibodies. *Br J Haematol* 1990; 76: 101-107.
124. Marciniak E, Romond EH. Impaired catalytic function of activated protein C: a new in vitro manifestation of lupus anticoagulant. *Blood* 1989; 74: 2426-2432.
125. Borrell M, Sala N, Castellarnau C, Lopez S, Gari M, Fontcuberta J. Immunoglobulin fractions isolated from patients with antiphospholipid antibodies prevent the inactivation of factor Va by activated protein C on human endothelial cells. *Thromb Haemost* 1992; 68: 268-272.
126. Dahlbäck B, Carlsson M, Svensson PJ. Familial thrombophilia due to a previously unrecognized mechanism characterized by poor anticoagulant response to activated protein C: prediction of a cofactor to activated protein C. *Proc Natl Acad Sci* 1993; 90: 1004-1008.
127. Svensson PJ, Dahlbäck B. Resistance to protein C as a basis for venous thrombosis. *N Engl J Med* 1994; 330: 517-522.
128. Bertina RM, Koeleman BPC, Koster T et al. Mutation in blood coagulation factor V associated with resistance to activated protein C. *Nature* 1994; 369: 64-67.
129. Seligsohn U, Lubetsky A. Genetic susceptibility to venous thrombosis. *N Engl J Med* 2001; 344: 1222-1231.

- 
130. Cumming AM, Tait RC, Fildes S, Yoong A, Keeney S, Hay CRM. Development of resistance to activated protein C during pregnancy. *Br J Haematol* 1995; 90: 725-727.
131. Rosing J, Middeldorp S, Curvers J et al. Low-dose oral contraceptives and acquired resistance to activated protein C: a randomised cross-over study. *Lancet* 1999; 354: 2036-2040.
132. Pablos JL, Caliz RA, Carreira PE, Atsumi T, Serrano L, Amengual O et al. Risk of thrombosis in patients with antiphospholipid antibodies and factor V Leiden mutation. *J Rheumatol* 1999; 26: 588-590.
133. Dizon-Townson D, Hutchison C, Silver R, Branch DW, Ward K. The factor V Leiden mutation which predisposes to thrombosis is not common in patients with antiphospholipid syndrome. *Thromb Haemost* 1995; 74: 1029-1031.
134. Sasso EH, Suzuki LA, Thompson AR, Petri MA. Hereditary resistance to activated protein C: an uncommon risk factor for thromboembolic disease in lupus patients with antiphospholipid antibodies. *Arthritis Rheum* 1997; 40: 1720-1721.
135. Bengtsson A, Zöller B, de Frutos PG, Dahlbäck B, Sturfelt G. Factor V:Q<sup>506</sup> mutation and anticardiolipin antibodies in systemic lupus erythematosus. *Lupus* 1996; 5: 598-601.
136. Ruiz-Argüelles GJ, Garcés-Eisele J, Alarcón-Segovia D, Ruiz-Argüelles A. Activated protein C resistance phenotype and genotype in patients

- with primary antiphospholipid syndrome. *Blood Coag Fibrinol* 1996; 7: 344-348.
137. Male C, Mitchell L, Julian J, Vegh P, Joshua P, Adams M et al. Acquired activated protein C resistance is associated with lupus anticoagulants and thrombotic events in pediatric patients with systemic lupus erythematosus. *Blood* 2001; 97: 844-849.
138. Ehrenforth S, Radtke KP, Scharrer I. Acquired activated protein C-resistance in patients with lupus anticoagulants. *Thromb Haemost* 1995; 74: 797-798.
139. Tsakiris DA, Yasikoff ML, Wolf F, Marbet GA. Anticardiolipin antibodies do not seem to be associated with APC resistance in vivo or in vitro. *Ann Hematol* 1995; 71: 195-198.
140. Martinuzzo M, Forastiero R, Adamczuk Y, Cerrato G, Carreras O. Activated protein C resistance in patients with anti- $\beta$ 2 glycoprotein I antibodies. *Blood Coag Fibrinol* 1996; 7: 702-704.
141. Ieko M, Ichikawa K, Triplett DA, Matsuura E, Atsumi T, Sawada K et al.  $\beta$ 2-Glycoprotein I is necessary to inhibit protein C activity by monoclonal anticardiolipin antibodies. *Arthritis Rheum* 1999; 42: 167-174.
142. Key NS. Toward an understanding of the pathophysiologic mechanism of thrombosis in the antiphospholipid syndrome. *J Lab Clin Med* 1995; 125: 16-17.

143. van der Bom JG, Bots ML, Haverkate F, Slagboom PE, Meijer P, de Jong PT et al. Reduced response to activated protein C is associated with increased risk for cerebrovascular disease. *An Inter Med* 1996; 125: 265-269.
144. Kiechl S, Muigg A, Santer P, Mitterer M, Egger G, Oberhollenzer M et al. Poor response to activated protein C as a prominent risk predictor of advanced atherosclerosis and arterial disease. *Circulation* 1999; 99: 614-619.
145. Rai R, Shlebak A, Cohen H et al. Factor V Leiden and acquired activated protein C resistance among 1000 women with recurrent miscarriage. *Hum Reprod* 2001; 16: 961-965.
146. Younis JS, Brenner B, Ohel G, Tal J, Lanir N, Ben-Ami M. Activated protein C resistance and factor V Leiden mutation can be associated with first - as well as second-trimester recurrent pregnancy loss. *Am J Reprod Immunol* 2000; 43: 31-35.
147. Jouhikainen T, Kekomaki R, Leirisalo-Repo M, Backlund T, Myllyla G. Platelet autoantibodies detected by immunoblotting in systemic lupus erythematosus: association with the lupus anticoagulant, and with history of thrombosis and thrombocytopenia. *Eur J Haematol* 1990; 44:234-239.
148. Fabris F, Cordiano I, Borzini P, Luzzatto G, Randi ML et al. Specific antiplatelet antibodies in patients with antiphospholipid antibodies and thrombocytopenia. *Eur J Haematol* 1994; 53:232-236.

- 
149. Stoeber Z, Stoeber D, Green L, Geltner D. The role of anticardiolipin autoantibodies in the pathogenesis of autoimmune hemolytic anemia in systemic lupus erythematosus. *J Rheumatol* 1993; 20:2058-2061.
150. Tan EM, Cohen AS, Fries JF, Masi AT, McShane DJ, Rothfield NF et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. *Arthritis Rheum* 1982; 25:1271-1277.
151. Spronk PE, Limburg PC, Kallenberg CG. Serological markers of disease activity in systemic lupus erythematosus. *Lupus* 1995; 4:86-94.
152. Lockshin MD. Pregnancy loss and antiphospholipid antibodies. *Lupus* 1998; 7: S86-S89.
153. Stoeber ZM, Mozes E, Tartakovsky B. Anticardiolipin antibodies induce pregnancy failure by impairing embryonic implantation. *Proc Natl Acad Sci USA* 1993; 90:6464-6467.
154. Fishman P, Falach-Vaknine E, Zigelman R, Bakimer R, Sredni B, Djaldetti M et al. Prevention of fetal loss in experimental antiphospholipid syndrome by in vitro administration of recombinant interleukin-3. *J Clin Invest* 1993; 41:1834-1877.
155. Shurtz-Swirski R, Inbar O, Blank M, Cohen J, Bakimer R, Barnea ER et al. In vitro effect of anticardiolipin antibodies upon total and pulsatile placental hCG secretion during early pregnancy. *Am J Reprod Immunol* 1993; 29:206-210.



156. Galli M, Ruggeri L, Barbui T. Differential effects of anti- $\beta$ 2-glycoprotein I and antiprothrombin antibodies on the anticoagulant activity of activated protein C. *Blood* 1998; 91: 1999-2004.
157. Rosendaal FR, Siscovick DS, Schwartz SM et al. Factor V Leiden (resistance to activated protein C) increases the risk of myocardial infarction in young women. *Blood* 1997; 89: 2817-2821.
158. Doggen CJ, Cats VM, Bertina RM, Rosendaal FR. Interaction of coagulation defects and cardiovascular risk factors: increased risk of myocardial infarction associated with factor V Leiden or prothrombin 20210A. *Circulation* 1998; 97: 1037-1041.
159. Inbal A, Freimark D, Modan B et al. Synergistic effects of prothrombotic polymorphisms and atherogenic factors on the risk of myocardial infarction in young males. *Blood* 1999; 93: 2186-2190.